Exome Asset Management LLC: TG THERAPEUTICS INC (TGTX): Quarterly 13F Position History
As of Q2 2026, Exome Asset Management LLC reported 164,915 shares of TG THERAPEUTICS INC (TGTX), worth $9.1M and representing 5.6% of its 13F equity book. Quarter-over-quarter share count change: + 164,915 (re-initiated) . The position first appeared in Q4 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 164,915Shares Held (Latest Filing)
- $9.1MReported Market Value (Latest Filing)
- 5.6%Portfolio Weight (% of 13F Equity Book)
- +164,915Quarter-over-Quarter Share Change
- +$9.1MQuarter-over-Quarter Value Change
- 251,600Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 164,915 | +164,915 | – | $9.1M | 5.6% | $54.9 |
| Q1 2026 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2024 | 0 | 207,627 | -100.0% | $0 | 0.0% | – |
| Q3 2024 | 207,627 | 43,973 | -17.5% | $4.9M | 3.3% | $23.4 |
| Q2 2024 | 251,600 | +21,300 | +9.2% | $4.5M | 3.9% | $17.8 |
| Q1 2024 | 230,300 | +27,000 | +13.3% | $3.5M | 3.0% | $15.2 |
| Q4 2023 | 203,300 | – | – | $3.5M | 3.4% | $17.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Exome Asset Management LLC first disclose a TGTX position in 13F-HR filings?
Exome Asset Management LLC first reported TG THERAPEUTICS INC (TGTX) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Exome Asset Management LLC's most recent quarter-over-quarter share-count change in TGTX?
Between Q1 2026 and Q2 2026, Exome Asset Management LLC added 164,915 shares of TGTX (re-initiated), bringing the total reported position to 164,915 shares at a market value of $9.1M.
Does the implied price-per-share represent Exome Asset Management LLC's cost basis in TGTX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.